Title:Self-emulsifying Drug Delivery System for Oral Anticancer Therapy: Constraints
and Recent Development
Volume: 28
Issue: 31
Author(s): Mrugank Pandya, Bappaditya Chatterjee*Srikar Ganti
Affiliation:
- Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM’s NMIMS, Vile Parle West, Mumbai 400056,
India
Keywords:
Self-emulsifying, SEDDS, SNEDDS, anticancer, bioavailability, oral delivery.
Abstract: Oral anticancer therapy faces several drawbacks: low aqueous solubility, poor and irregular absorption
from gastrointestinal sites, high first-pass metabolism, food-influenced absorption, non-targeted delivery,
severe systemic and local adverse effects, etc. Enhancement of oral bioavailability could reduce the drug load
and associated adverse effects. Self-emulsifying drug delivery systems (SEDDS) can enhance in-vivo solubility
and drug absorption from the gastrointestinal tract, bypass liver metabolism by lymphatic absorption and inhibit
efflux transport. All these phenomena ultimately result in improved oral bioavailability. Anticancer drug delivery
using the SEDDS has shown promising results for bioavailability and pharmacodynamic response. A handful
of research studies have produced evidence of the successful loading of anticancer agents in SEDDS-based
formulations. Various potent and established chemotherapeutic agents such as docetaxel, paclitaxel, etoposide,
5 Fluorouracil, doxorubicin etc., have been successfully formulated and evaluated. Improved bioavailability and
reduction of dose might be possible by SEDDS. It could be effective for low-dose drugs. But, excessive surfactant-
cosurfactant concentration, lacking predictive in-vitro models and adequate IVIVC, and unavailability of
toxicity data are certain challenges for future researchers. No clinical trials have been recorded with anticancer
drug-loaded SEDDS. Overcoming the challenges and further progression to clinical studies are required to avail
the benefits of anticancer SEDDS.
